Cybin Prepares For GMP Manufacturing Of CYB003 Capsules For Phase 3 Trial
Portfolio Pulse from Happy Mohamed
Cybin Inc. (NYSE:CYBN) has initiated preparations for good manufacturing practices (GMP) production of a capsule formulation of CYB003, its proprietary deuterated psilocybin analog in development for the potential treatment of Major Depressive Disorder (MDD). The company plans to ship CYB003 capsules to clinical sites in Q1 2024. The company has also been granted a U.S. patent for the composition of matter claims and treatment methods in support of the CYB003 program until 2041.
August 17, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cybin Inc. is preparing for GMP production of CYB003 capsules, a potential treatment for Major Depressive Disorder. The company expects to ship the capsules to clinical sites in Q1 2024 and has been granted a U.S. patent for the CYB003 program until 2041.
The news about Cybin Inc. initiating preparations for GMP production of CYB003 capsules and the granted U.S. patent for the CYB003 program until 2041 is positive. This could potentially increase investor confidence in the company's ability to develop and commercialize its product, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100